Form D · Biotechnology
Q-State PainCo, Inc.
Cambridge, MA · CIK 0001756810
Offering snapshot reported Oct 25, 2018 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 4, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 25, 2018 | Initial | $2,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-324315
Issuance of convertible promissory notes.
Source: Form D, filed Oct 25, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Margulies | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Q State Biosciences, Inc. 179 Sidney Street
Cambridge, MA, 02139
Cambridge, MA, 02139